tiprankstipranks
Advertisement
Advertisement

TGTX Stock Latest News

TGTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Pre-EarningsTGTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
13h ago
TGTX
TG Therapeutics price target raised to $86 from $55 at B. Riley
PremiumThe Fly
TG Therapeutics price target raised to $86 from $55 at B. Riley
5d ago
TGTX
Analyst Tara Bancroft Raises TG Therapeutics Price Target to $75 on Strong Long-Term Briumvi Growth Outlook
PremiumRatings
Analyst Tara Bancroft Raises TG Therapeutics Price Target to $75 on Strong Long-Term Briumvi Growth Outlook
11d ago
TGTX
TG Therapeutics Targets Myasthenia Gravis Growth With New BRIUMVI Trial
PremiumCompany Announcements
TG Therapeutics Targets Myasthenia Gravis Growth With New BRIUMVI Trial
15d ago
TGTX
TG Therapeutics price target raised to $20 from $17 at BofA
PremiumThe Fly
TG Therapeutics price target raised to $20 from $17 at BofA
25d ago
TGTX
TG Therapeutics: Buy Rating Reaffirmed as Briumvi Schizophrenia Trial Adds Upside Optionality; $70 Price Target Unchanged
PremiumRatingsTG Therapeutics: Buy Rating Reaffirmed as Briumvi Schizophrenia Trial Adds Upside Optionality; $70 Price Target Unchanged
26d ago
TGTX
TG Therapeutics initiates Briumvi clinical trial
Premium
The Fly
TG Therapeutics initiates Briumvi clinical trial
26d ago
TGTX
TG Therapeutics price target raised to $83 from $57 at Jefferies
Premium
The Fly
TG Therapeutics price target raised to $83 from $57 at Jefferies
1M ago
TGTX
TG Therapeutics Shareholders Reject Executive Compensation at Meeting
PremiumCompany Announcements
TG Therapeutics Shareholders Reject Executive Compensation at Meeting
2M ago
8K
TGTX
TG Therapeutics: Buy Rating Reiterated on Briumvi Expansion Strategy, $70 Price Target Unchanged
PremiumRatings
TG Therapeutics: Buy Rating Reiterated on Briumvi Expansion Strategy, $70 Price Target Unchanged
2M ago
TGTX
TG Therapeutics announces Briumvi data, initiates clinical trial
PremiumThe Fly
TG Therapeutics announces Briumvi data, initiates clinical trial
2M ago
TGTX
Corinne Johnson Reiterates Hold Rating on Briumvi Developer, Keeps Price Target Unchanged at $41 Amid Long-Term Potential and Execution Risks
PremiumRatings
Corinne Johnson Reiterates Hold Rating on Briumvi Developer, Keeps Price Target Unchanged at $41 Amid Long-Term Potential and Execution Risks
2M ago
TGTX
TG Therapeutics rises 10.6%
PremiumThe FlyTG Therapeutics rises 10.6%
2M ago
TGTX
TG Therapeutics announces results from Briumvi trial
Premium
The Fly
TG Therapeutics announces results from Briumvi trial
2M ago
TGTX
TG Therapeutics reports positive data for subcutaneous BRIUMVI
Premium
Company Announcements
TG Therapeutics reports positive data for subcutaneous BRIUMVI
2M ago
8K
TGTX
TG Therapeutics publishes data analyses from ULTIMATE I, II studies
PremiumThe Fly
TG Therapeutics publishes data analyses from ULTIMATE I, II studies
2M ago
TGTX
TG Therapeutics reports positive Phase 3 ENHANCE trial results
PremiumCompany Announcements
TG Therapeutics reports positive Phase 3 ENHANCE trial results
2M ago
8K
TGTX
Morning Movers: Dycom skyrockets after first quarter results
PremiumThe Fly
Morning Movers: Dycom skyrockets after first quarter results
2M ago
DY
ZS
TG Therapeutics reports ENHANCE trial meets primary endpoint
PremiumThe Fly
TG Therapeutics reports ENHANCE trial meets primary endpoint
2M ago
TGTX
TG Therapeutics reports Q1 EPS 12c, consensus 28c
PremiumThe FlyTG Therapeutics reports Q1 EPS 12c, consensus 28c
3M ago
TGTX
TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright
Premium
The Fly
TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright
3M ago
TGTX
TG Therapeutics Earnings Call Highlights Explosive Growth
Premium
Company Announcements
TG Therapeutics Earnings Call Highlights Explosive Growth
3M ago
TGTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >